Arcutis Biotherapeutics (ARQT) Payables: 2020-2025
Historic Payables for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $5.8 million.
- Arcutis Biotherapeutics' Payables fell 70.01% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.6 million, marking a year-over-year increase of 14.16%. This contributed to the annual value of $14.2 million for FY2024, which is 18.58% up from last year.
- Per Arcutis Biotherapeutics' latest filing, its Payables stood at $5.8 million for Q3 2025, which was down 61.58% from $15.1 million recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' Payables ranged from a high of $24.5 million in Q1 2025 and a low of $2.7 million during Q2 2021.
- Over the past 3 years, Arcutis Biotherapeutics' median Payables value was $13.2 million (recorded in 2023), while the average stood at $14.1 million.
- Its Payables has fluctuated over the past 5 years, first soared by 296.25% in 2022, then slumped by 70.01% in 2025.
- Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Payables stood at $7.4 million in 2021, then grew by 20.05% to $8.8 million in 2022, then skyrocketed by 35.86% to $12.0 million in 2023, then increased by 18.58% to $14.2 million in 2024, then crashed by 70.01% to $5.8 million in 2025.
- Its Payables stands at $5.8 million for Q3 2025, versus $15.1 million for Q2 2025 and $24.5 million for Q1 2025.